Passa al contenuto
Merck

Vai a

3010

Transcreener® ADP2 FP Assay

Sinonimo/i:

Transcreener assay

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
1000 assays
Per conoscere la disponibilità, visualizza il carrello
CHF 754.00
10000 assays
Per conoscere la disponibilità, visualizza il carrello
CHF 4’160.00

Informazioni su questo articolo

NACRES:
NA.81
UNSPSC Code:
41122100

CHF 754.00


Per conoscere la disponibilità, visualizza il carrello

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


shipped in

dry ice

storage temp.

−20°C

General description

The Transcreener® HTS Assay platform overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by utilizing a single set of assay reagents that detect an invariant product. The generic nature of the Transcreener® HTS Assay platform eliminates delays involved in assay development for new HTS targets, and greatly simplifies compound and inhibitor profiling across multiple target families.

The Transcreener® ADP2 FP Assay is a far-red, competitive fluorescence polarization (FP) assay based on the detection of ADP and therefore is compatible with any enzyme class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA helicases, carboxylases and glutamine synthetase. The Transcreener® ADP2 Assay is a simple one step homogenous detection assay, and is extremely flexible with regard to ATP concentration (0.1 to 1,000 μM ATP). The assay provides excellent signal at low substrate conversion, with a Z′ = 0.7 and = 85 polarization shift (mP) at 10% ATP conversion using 1 μM ATP.

The Transcreener® ADP2 FP Assay was developed to follow the progress of any enzyme that produces ADP. The Transcreener® ADP Detection Mixture comprises an ADP Alexa633 Tracer bound to an ADP2 Antibody. The tracer is displaced by ADP, the invariant product generated during the enzyme reaction.The displaced tracer freely rotates leading to a decrease in fluorescence polarization. The assay uses a far red tracer to minimize interference from fluorescent compounds and light scattering.

View full Transcreener® product list

Physical form

Kit with buffered aqueous solutions

Preparation Note

3010-1K = 1,000 assay, 384-well
3010-10K = 10,000 assay, 384-well

Legal Information

Transcreener is a registered trademark of BellBrook Labs

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
301130203013
shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C


signalword

Warning

Classe di stoccaggio

12 - Non Combustible Liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

target_organs

Respiratory Tract

pictograms

Health hazardExclamation mark

hcodes

Hazard Classifications

Eye Irrit. 2 - STOT RE 2 Inhalation



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti


Protocolli

Jump dilution protocol to determine the residence time of a drug (or drug candidate) during its interaction with a kinase using a fluorescence polarization assay based on the detection of ADP.


Peng Su et al.
International journal of clinical and experimental pathology, 7(6), 3008-3017 (2014-07-18)
IMP3 plays an important role in tumor invasion and metastasis, to which epithelial to mesenchymal transition (EMT) also contributes. The purpose of this study was to investigate whether IMP3 can regulate invasion and metastasis through EMT in breast cancers. The
Nathalie Boone et al.
PloS one, 5(12), e15590-e15590 (2010-12-29)
Familial dysautonomia (FD) is a hereditary neuropathy caused by mutations in the IKBKAP gene, the most common of which results in variable tissue-specific mRNA splicing with skipping of exon 20. Defective splicing is especially severe in nervous tissue, leading to
Founders of the first Hungarian Physiological Association in 1891.
E Monos et al.
Acta physiologica Hungarica, 97(1), 60-61 (2010-03-18)



Numero articolo commerciale globale

SKUGTIN
151815-10X0.75ML04061838739575
151815-10X1ML04061838739582
175870-25G04061838752574
175870-10X0.8ML-N04061837613401
175978-10G04061838752611
175978-50G04061838752628
175870-5G04061837613425
48940-U04061832401669
101766000904022536024455
101789000004061839633506
570680-50G04061832597393
151815-50G04061837648861
151815-10X50G-N04061837648854
151815-100G04061837648847
151815-25G04061838739599
151815-10G-AMP04061837613098
151815-10G-GL04061838739568
175870-10X1ML04061837613418
175870-10X0.5ML04061838752567

Questions

Reviews

No rating value

Active Filters